A Study of Mocertatug Rezetecan in Combination With Anti-cancer Therapies for Advanced Solid Tumors (BEHOLD-2)
Tumours, Gynecological
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 305 (planned)
- Started
- Mar 4, 2025
- Main results expected
- Jun 21, 2027
- Fully finished
- Oct 10, 2028
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Part A: Percentage of participants with dose limiting toxicities (DLTs)
Measured over: Approximately 7 months
Part A: Number of participants with adverse events (AEs), immune-mediated adverse events (imAEs), adverse events of special interest (AESI), serious adverse events (SAEs) by Severity
Measured over: Up to approximately 22 months
Part A: Number of participants with adverse events (AEs), immune-mediated adverse events (imAEs), adverse events of special interest (AESI), serious adverse events (SAEs) by Frequency
Measured over: Up to approximately 22 months
Part B: Confirmed Objective Response Rate (ORR)
Measured over: Up to approximately 37 months
Changes Tremor has spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT06796907 · record last updated 2026-11-02 · checked 2026-11-09 15:47 UTC